Characteristics of patients presented with metastases during or after completion of chemo-radiation therapy (CRT) for locally advanced rectal cancer: a case series

Torky, Radwan; Alessa, Mohammed Yousef; Kim, Ho Seung; Sakr, Ahmed; Zakarneh, Eman; Sauri, Fozan; Bae, Heejin; Kim, Nam Kyu

doi:10.3393/ac.2020.08.10.1

Cited by 6 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is known that 25% of patients with CRC are diagnosed with liver metastases at the initial diagnosis and 50%-70% of patients are diagnosed with metachronous liver metastasis after resection of primary cancer [11,12]. In the treatment of patients with CRC with liver metastasis, liver resection with or without local ablation therapy can be used for curative treatment [13]. The EORTC CLOCC trial resulted in a longer progression-free survival for the radiofrequency ablation plus chemotherapy group than for the group that underwent systemic treatment [14].…”

Section: Liver Metastasis In Mcrcmentioning

confidence: 99%

Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version

Park

Baik

2022

J Anus Rectum Colon

View full text Add to dashboard Cite

Stage IV colorectal cancer (CRC) has heterogeneous characteristics in tumor extent and biology. The overall survival of patients with metastatic CRC has improved with the development of multimodal treatments and new chemotherapeutic drugs. Resection of metastatic CRC is performed for liver, lung, or peritoneal metastases. Conversion surgeries to resect oligometastatic lesions have been developed with tumor regression using chemotherapeutic agents. Two-stage hepatectomy has extended the surgical indications for patients with metastatic CRC. Synchronous liver and primary tumor resection can be considered in patients with adequate conditions. Local ablation with radiotherapy can be used to treat lung metastasis. In the treatment of patients with CRC with peritoneal metastasis, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy can be considered. Surgical treatments should be performed in patients with symptomatic primary tumors with unresectable metastasis. However, primary tumor resection in patients with asymptomatic CRC with synchronous, unresectable metastases did not show overall survival benefits in recent studies. Therefore, the treatment of metastatic CRC is challenging due to the variable tumor extent and heterogenous characteristics. Tailored surgical treatments and multidisciplinary approaches may improve survival and the quality of life in patients with metastatic CRC.

show abstract

Section: Liver Metastasis In Mcrcmentioning

confidence: 99%

Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version

Park

Baik

2022

J Anus Rectum Colon

View full text Add to dashboard Cite

show abstract

“…Chemotherapy is the major treatment for CRC that has spread to other organs, and surgery is only occasionally employed. However, with advancements in systemic therapy, increased use of genetic information, and the development of surgical techniques, more individuals with metastatic CRC can benefit from curative-intent surgical surgery [16][17][18].…”

Section: Development Surgical Treatment Of Metastatic Colorectal Cancermentioning

confidence: 99%

Update on Diagnosis and Treatment of Colorectal Cancer

Kim¹

2022

Ewha Med J

View full text Add to dashboard Cite

The rate of colorectal cancer (CRC) has altered. Early-onset CRC patients are increasing, and it is one of the main causes of cancer-related death. Based on epidemiologic change, the CRC screening program needs to be changed. To increase compliance, non-invasive screening techniques are developed. Although CRC survival has increased, the oncologic prognosis of metastatic CRC is remains poor. Even in metastatic CRC, which is the most difficult to treat, attempts are being made to increase the survival rate by active surgical therapy with the creation of chemotherapeutic regimens and targeted treatment based on genomic information. Due to the introduction of aggressive chemotherapy regimens, targeted therapy based on genomic features, and improvements in surgical technique, the role of surgical treatment in metastatic CRC has expanded. Metastatic CRC surgery was indicated for liver, lung, and even peritoneal seeding. Local ablation therapy was also effectively used for liver and lung metastasis. Cytoreductive surgery and intraperitoneal chemotherapy were tried for peritoneal seeding and demonstrated good results in a subgroup of patients, although the right indication was carefully assessed. At the same time, one of the key goals of treatment for CRC was to maintain functional outcomes. Neoadjuvant treatment, in particular, helped rectal cancer patients preserve functional results while maintaining oncologic safety. Rectal cancer organ preservation techniques are now being researched heavily in a variety of neoadjuvant treatment settings, including immunotherapy and whole neoadjuvant therapy. Precision medicine based on patient and disease characteristics is currently being used for the diagnosis and treatment of CRC.

show abstract

“…Thus, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was developed for peritoneal malignancies to overcome these limitations. Since colorectal surgical techniques have advanced over several decades [4][5][6], chemoradiotherapy and extensive lymphadenectomy involving multivisceral resection can be used to treat patients with CRC from the early stages to stage IV [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Jeon,

Park

2023

Ewha Med J

View full text Add to dashboard Cite

In stage IV colorectal cancer (CRC), peritoneal metastasis is associated with a poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) is an effective treatment option that offers survival benefits in patients with peritoneal metastatic CRC. For over the past several decades, a multitude of studies have been conducted on CRS and HIPEC for peritoneal metastatic diseases, and research in this area is ongoing. Proper patient selection and a meticulous preoperative assessment are crucial for achieving successful postoperative outcomes. The completeness of cytoreduction and the surgical techniques employed are key factors in improving oncologic outcomes following CRS and HIPEC. The role of HIPEC for both therapeutic and prophylactic purposes is currently being evaluated in recent clinical trials. This article reviews the fundamental principles of CRS combined with HIPEC and discusses recent clinical trials concerning the treatment of CRS and HIPEC in CRC patients with peritoneal carcinomatosis.

show abstract

Characteristics of patients presented with metastases during or after completion of chemo-radiation therapy (CRT) for locally advanced rectal cancer: a case series

Cited by 6 publications

References 25 publications

Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version

Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version

Update on Diagnosis and Treatment of Colorectal Cancer

Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Contact Info

Product

Resources

About